Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma

Table 2 Factors and prognosis of patients with LPA by Univariate Analysis

Factors	n	5-year survival (%)	p
Sex
Male	30	54.73	0.7494
Female	51	46.43
Smoking
No	53	56.39	0.1286
yes	28	40.56
Proportion of lepidic growth (BAC) in adenocarcinoma^*
≤50% (including 0%)	50	35.69	0.0375
>50%	31	58.32
Age
≤60 years	25	52.85	0.6028
>60 years	56	47.74
Location
Central	7	42.86	0.2521
Peripheral	74	50.47
Staging
I	50	69.87	0.0002
II	26	38.46
III	5	15.63
T stage
T1	43	60.63	0.0142
≥T2	38	43.38
N stage
N0	62	63.20	0.0004
N1	16	38.46
N2	3	15.63
Surgical procedure
Lobectomy	79	53.85
Pneumonectomy	2	49.12
Laterality
Left	38	52.12	0.2873
Right	43	48.29
ECOG performance status
0	75	50.83	0.4872
1	6	49.15
Histologic differentiation
Well	58	60.37	0.0089
Moderate/poorly	23	41.28
Claudin 1
-	33	26.75	0.0034
+	48	63.20
c-fos
-	28	55.19	0.8438
+	53	29.43
Claudin 10
-	25	30.30	0.0019
+	56	59.75
MMP-2
-	19	12.00	0.3208
+	62	41.81
Combination of CLDN1&CLDN10
both factors expressed	35	68.90	0.0000
either factor expressed	35	44.32
neither factor expressed	11	0

^*: We defined 50% as a cutoff for lepidic growth in these tumors because some studies showed that if the lepidic growth was more than 50%, the 5-year survival of patients with T1 lung adenocarcinoma was much better than those with less than 50% lepidic growth [6–9].

ISSN: 1749-8090